Financial Comparison: Arvinas (ARVN) & Its Rivals

Arvinas (NASDAQ:ARVN – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Arvinas to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Arvinas and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas 1 3 6 0 2.50
Arvinas Competitors 9951 15359 45765 1602 2.54

Arvinas currently has a consensus target price of $15.18, suggesting a potential upside of 135.38%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Arvinas’ higher probable upside, research analysts plainly believe Arvinas is more favorable than its competitors.

Valuation and Earnings

This table compares Arvinas and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Arvinas $262.60 million -$80.80 million -26.88
Arvinas Competitors $688.58 million $7.69 million -17.98

Arvinas’ competitors have higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Arvinas has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Arvinas’ competitors have a beta of -1.85, meaning that their average share price is 285% less volatile than the S&P 500.

Profitability

This table compares Arvinas and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arvinas -3.45% -2.00% -1.43%
Arvinas Competitors -12,224.75% -204.85% -31.52%

Summary

Arvinas competitors beat Arvinas on 7 of the 13 factors compared.

Arvinas Company Profile

(Get Free Report)

Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, that develops medicines using targeted protein degradation. Founded in 2013, the company applies its PROTAC technology to direct disease-related proteins for removal by the body’s natural protein-disposal system. Its research focuses primarily on cancer, including investigational therapies designed to target estrogen and androgen receptors. The company’s programs include vepdegestrant, an estrogen receptor degrader being developed with Pfizer for certain forms of breast cancer, as well as androgen receptor degraders being studied for prostate cancer.

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.